Clinical outcome of allogeneic hematopoietic stem cell transplantation in the treatment of 9 myeloid leukemia patients with granulocytic sarcoma
10.3760/cma.j.issn.0578-1426.2018.03.013
- VernacularTitle:异基因造血干细胞移植治疗合并粒细胞肉瘤的髓系白血病九例分析
- Author:
Lijie LIANG
1
;
Jian ZHOU
;
Yanli ZHANG
;
Yuewen FU
;
Yingling ZU
;
Fengkuan YU
;
Quande LIN
;
Lijie HAN
;
Qian WANG
;
Baijun FANG
;
Xudong WEI
;
Yongping SONG
Author Information
1. 450003,郑州大学附属肿瘤医院河南省肿瘤医院血液科河南省血液病研究所
- Keywords:
Granulocytic sarcoma;
Allogeneic hematopoietic stem cell transplantation;
Myeloid leukemia
- From:
Chinese Journal of Internal Medicine
2018;57(3):216-219
- CountryChina
- Language:Chinese
-
Abstract:
To explore the efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloid leukemia and granulocytic sarcoma (GS).Clinical outcome including hematopoietic reconstitution,transplant-related complications,survival and relapse were collected and retrospectively analyzed in 9 patients with myeloid leukemia and GS after allo-HSCT.Hematopoiesis reconstitution was achieved in all the 9 recipients.Four cases developed acute graft-versus-host disease (GVHD),and 1 with chronic GVHD.The median follow-up time after transplantation was 10(4-81) months.Only 2 cases survived,the other 7 died of relapse.The median time of relapse after transplantation was 5(3-19) months.Allo-HSCT is relatively effective treatment for patients with myeloid leukemia and GS.Relapse after transplantation remains the major factor of mortality.
